🔗 Permalink

Inventor profile of:

Arnold Munnich

City:

Paris

Country:

France

Published Applications:

Last publication date:

2026-04-02

Top Assignees for applications by Arnold Munnich

The entities that hold a legal rights for patent applications filed by inventor Munnich Arnold:

INSERM INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) 5 Paris, France
Institut National De La Sante Et De La Recherche Medicale (INSERM) 3 Paris, France
IMAGINE 3 Paris, France
Institut National de la Sante et de la Recherche Medicale 3 Paris, France
UNIVERSITE PARIS DESCARTES 3 Paris, France
Centre National de la Recherche Scientifique (CNRS 3 Paris, France
Assistance Publique-Hopitaux De Paris 2 Paris, France
UNIVERSITE PARIS DESCARTES - PARIS V 2 Paris, France
UNIVERSITÉ PARIS CITÉ 2 Paris, France
ASSISTANCE PUBLIQUE -HÔPITAUX DE PARIS (APHP) 2 Paris, France
FONDATION IMAGINE 2 Paris, France
IPSEN PHARMA S.A.S. 1 Boulogne-Billancourt, France
FOUNDATION IMAGINE 1 Paris, France
INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE 1 PARIS CEDEX 13, France
UNIVERSITE PARIS CITE 1 Paris, France
Assitance Publique-Hopitaux de Paris 1 Paris, France
INSERM 1 PARIS, France
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (APHP) 1 Paris, France
Universite Paris Diderot-Paris 7 1 Paris, France
ASSISTANCE PUBLIQUE-HOPITAUX DE PARIS (AP-HP) 1 Paris, France

Recent patent applications by Munnich Arnold

Arnold Munnich from Paris, FR has applied for patents for these inventions. The list has both pending applications and granted patents:

#1 | 2026-04-02

US20260091033A1

Human necessities

ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3

#2 | 2024-10-24

US20240350490A1

Human necessities

ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3

#3 | 2024-04-11

US20240117344A1

Chemistry; metallurgy

METHODS FOR PERFORMING ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING IN THE RETINA OF A SUBJECT IN NEED THEREOF

#4 | 2023-03-09

US20230075776A1

Human necessities

ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3

#5 | 2022-04-07

US20220105073A1

Human necessities

Treatment and prediction of therapeutic responses in patients suffering from Friedreich ataxia

#6 | 2022-02-03

US20220031696A9

Human necessities

Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3

#7 | 2020-08-06

US20200246337A1

Human necessities

Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3

#8 | 2019-01-31

US20190037583A2

Electricity

Methods for performing antisense oligonucleotide-mediated exon skipping in the retina of a subject in need thereof

#9 | 2018-06-14

US20180161327A1

Human necessities

ANTAGONIST OF THE FIBROBLAST GROWTH FACTOR RECEPTOR 3 (FGFR3) FOR USE IN THE TREATMENT OR THE PREVENTION OF SKELETAL DISORDERS LINKED WITH ABNORMAL ACTIVATION OF FGFR3

#10 | 2016-12-22

US20160369348A1

Chemistry; metallurgy

METHODS FOR DIAGNOSING AND TREATING MYHRE SYNDROME

#11 | 2016-05-26

US20160150555A1

Electricity

METHODS FOR PERFORMING ANTISENSE OLIGONUCLEOTIDE-MEDIATED EXON SKIPPING IN THE RETINA OF A SUBJECT IN NEED THEREOF

#12 | 2016-02-25

US20160051549A1

Human necessities

Antagonist of the fibroblast growth factor receptor 3 (FGFR3) for use in the treatment or the prevention of skeletal disorders linked with abnormal activation of FGFR3

#13 | 2015-04-16